
zzso the safety and efficacy of zzso zzso zzso in adults with chronic zzso low back zzso 

zzso zzso Food and Drug Administration approved pilot zzso 

Three centers in the United zzso 

Fifteen adults with zzso single, or zzso zzso zzso zzso pain confirmed through meticulous provocation zzso 

zzso and zzso zzso delivery of zzso zzso zzso zzso with the zzso zzso Device into symptomatic zzso zzso 

zzso were performed at zzso 72 hours, and 1, 4, 13, 26, 52, and 104 weeks following zzso Potential adverse events were evaluated with serial assessment of neurological status, zzso and magnetic resonance imaging zzso zzso measures included serial assessments of low back pain visual analog scale zzso zzso and the zzso zzso zzso zzso 

Safety neurological zzso zzso and zzso showed no significant zzso zzso events were reported in nine zzso Two instances of low back muscle zzso and one case of zzso were the only events considered related to the procedure or zzso 

Mean low back pain zzso scores zzso decreased from zzso zzso confidence zzso zzso at baseline to zzso zzso zzso zzso and zzso zzso mean zzso score improved from zzso zzso at baseline to zzso zzso zzso zzso and zzso zzso at 26, 52, and 104 weeks, zzso 

zzso injection of zzso zzso zzso zzso with the zzso zzso Device appears safe and may improve pain and function in selected patients with zzso zzso 

